[ad_1]
Scientists at Nanyang Technological University (NTU) in Singapore have developed a new diagnostic test capable of detecting SARS-CoV-2, responsible for Covid-19, even when it mutates.
Viruses have the ability to evolve over time, and a diagnostic test to detect the virus even after potential mutations will be useful in tracking and combating the pandemic.
Multiple variants of the virus have already emerged, including some variants that are believed to have been widely spread in the UK, South Africa and Brazil.
The new Variant Nucleotide Guard (VaNGuard) assay uses a gene editing tool known as CRISPR, which is widely used in scientific research to alter DNA sequences and alter the function of genes in human cells in laboratory conditions.
It provides results in 30 minutes and can be used directly on raw patient samples in a clinical setting without RNA purification.
Scientists from NTU Schools of Chemical and Biomedical Engineering, Biological Sciences, Computer Science and Engineering; National university health system; and A * STAR developed the test.
Tan Meng How, associate professor at NTU’s School of Chemical and Biomedical Engineering, said, “Viruses are very intelligent. They can mutate, modify, or mix their genetic material, which means diagnostic tests may not catch them.
“Therefore, we have devoted considerable effort to developing a robust and sensitive test that can catch viruses even when they alter their genetic sequences.
“In addition, frequent testing is essential to help break down virus transmission within populations, which is why we have developed our tests to be rapid and affordable, making them deployable in low-pressure environments. resources.”
The VaNGuard test uses a reaction mixture containing enAsCas12a, a variant of the Cas12a enzyme, which acts like a pair of “molecular scissors”.
The enzyme targets specific segments of the genetic material of SARS-CoV-2 and cuts them off from the rest of its viral genome. By successfully cutting these segments, it identifies the presence of the virus.
The research team has filed a patent for the VaNGuard test and plans to obtain regulatory approval from the relevant authorities to market it in partnership with diagnostic companies.
[ad_2]
Source link
